The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone, J. Pathol, vol.242, pp.73-89, 2017. ,
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review, Cancer Treat. Rev, vol.40, pp.86-92, 2014. ,
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool, Br. J. Cancer, vol.103, pp.759-764, 2010. ,
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer, J. Natl. Cancer Inst, vol.99, pp.167-170, 2007. ,
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival, Clin. Cancer Res, vol.11, pp.951-958, 2005. ,
Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the american college of surgeons oncology group Z1031 trial (Alliance), 2017. ,
, J. Clin. Oncol, vol.35, pp.1061-1069
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031, J. Clin. Oncol, vol.29, pp.2342-2349, 2011. ,
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J. Natl. Cancer Inst, vol.100, pp.1380-1388, 2008. ,
Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours, Histopathology, vol.69, pp.849-861, 2016. ,
Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients, Breast Cancer Res. Treat, vol.118, pp.433-441, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00535315
Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers, Oncotarget, vol.8, pp.26122-26128, 2017. ,
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study, Breast Cancer Res. Treat, 2018. ,
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature, Ann. Oncol, vol.26, pp.2419-2428, 2015. ,
Highlights from the 15th St Gallen International Breast Cancer Conference 15, Ecancermedicalscience, vol.11, p.732, 2017. ,
A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers, Mol. Oncol, vol.8, pp.1441-1457, 2014. ,
An international study to increase concordance in Ki67 scoring, Mod. Pathol, vol.28, pp.778-786, 2015. ,
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer, Mod. Pathol, vol.32, pp.59-69, 2018. ,
Improving response to hormone therapy in breast cancer: new targets, new therapeutic options, Am. Soc. Clin. Oncol. Educ. Book, vol.35, 2016. ,
Accurate prediction and validation of response to endocrine therapy in breast cancer, J. Clin. Oncol, vol.33, pp.2270-2278, 2015. ,
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion, Cancer Res, vol.72, pp.3593-3606, 2012. ,